Catalent (NYSE:CTLT) had its price target increased by Robert W. Baird from $74.00 to $80.00 in a research note issued to investors on Friday morning, The Fly reports. They currently have an outperform rating on the stock.
Other analysts also recently issued reports about the stock. UBS Group boosted their target price on shares of Catalent from $70.00 to $77.00 and gave the company a buy rating in a research note on Wednesday, May 6th. Argus initiated coverage on shares of Catalent in a research note on Thursday, June 25th. They issued a buy rating on the stock. Deutsche Bank upped their price target on shares of Catalent from $59.00 to $62.00 and gave the stock a hold rating in a research note on Wednesday, May 6th. Zacks Investment Research downgraded shares of Catalent from a buy rating to a hold rating in a research note on Friday, June 5th. Finally, Royal Bank of Canada initiated coverage on shares of Catalent in a research note on Monday, April 20th. They issued an outperform rating and a $65.00 price target on the stock. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $74.71.
Shares of NYSE:CTLT opened at $71.94 on Friday. The company’s fifty day moving average is $74.17 and its two-hundred day moving average is $60.50. The company has a quick ratio of 1.58, a current ratio of 1.90 and a debt-to-equity ratio of 1.34. Catalent has a 12-month low of $31.04 and a 12-month high of $80.52. The company has a market cap of $11.32 billion, a P/E ratio of 102.77, a price-to-earnings-growth ratio of 4.35 and a beta of 1.65.
In related news, insider Aristippos Gennadios sold 8,325 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $73.00, for a total value of $607,725.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.30% of the company’s stock.
A number of large investors have recently modified their holdings of CTLT. Norges Bank bought a new stake in Catalent in the fourth quarter worth $83,479,000. Tower House Partners LLP bought a new stake in Catalent during the first quarter valued at about $44,158,000. Thrivent Financial for Lutherans boosted its holdings in Catalent by 91.0% during the first quarter. Thrivent Financial for Lutherans now owns 1,632,214 shares of the company’s stock valued at $84,794,000 after acquiring an additional 777,658 shares during the period. Champlain Investment Partners LLC boosted its holdings in Catalent by 17.4% during the fourth quarter. Champlain Investment Partners LLC now owns 4,851,205 shares of the company’s stock valued at $273,123,000 after acquiring an additional 719,325 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Catalent by 9.9% during the first quarter. JPMorgan Chase & Co. now owns 7,108,714 shares of the company’s stock valued at $369,298,000 after acquiring an additional 637,881 shares during the period.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More: How does quantitative easing work?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.